(NYSE: ANVS) Annovis Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.04%.
Annovis Bio's earnings in 2025 is -$30,260,143.On average, 7 Wall Street analysts forecast ANVS's earnings for 2025 to be -$25,004,732, with the lowest ANVS earnings forecast at -$27,308,004, and the highest ANVS earnings forecast at -$15,550,012. On average, 7 Wall Street analysts forecast ANVS's earnings for 2026 to be -$24,209,693, with the lowest ANVS earnings forecast at -$28,835,725, and the highest ANVS earnings forecast at -$5,933,557.
In 2027, ANVS is forecast to generate -$22,062,311 in earnings, with the lowest earnings forecast at -$31,700,201 and the highest earnings forecast at -$5,728,952.